Table 3

Multivariable analysis of CDAI over time

	Overall
	Coeff	95% CI	P values
Treatment at baseline
TCZ-IV	–	–
TCZ-SC	−0.76	−1.70 to 0.19	0.12
Time, years	−8.19	−8.87 to −7.51	<0.001
Time-squared	2.29	2.05 to 2.54	<0.001
Time-cubed	−0.18	−0.21 to −0.16	<0.001
Age, years	−0.02	−0.06 to 0.01	0.22
Female gender	−0.54	−1.66 to 0.58	0.34
Disease duration, years	−0.01	−0.07 to 0.05	0.72
Seropositivity	−1.85	−3.01 to −0.70	0.002
BMI	0.03	−0.05 to 0.12	0.45
Smoking	−0.32	−1.20 to 0.55	0.47
Glucocorticoids	1.68	1.01 to 2.34	<0.001
Concomitant csDMARD (base=none)	1.04	0.41 to 1.68	0.001
Any csDMARD MTX	1.51	0.81 to 2.21	<0.001
MTX+other csDMARDs	0.70	−0.60 to 2.00	0.29
Other than MTX	−0.07	−1.04 to 0.90	0.88
Previous bDMARDs (base=none)
1	0.42	−0.63 to 1.48	0.43
2	0.80	−0.36 to 1.96	0.18
≥3	0.06	−1.63 to 1.74	0.95
HAQ at baseline	3.87	3.25 to 4.50	<0.001
ESR	0.25	0.24 to 0.27	<0.001
Comorbidity	0.17	−0.80 to 1.14	0.73

bDMARD, biological disease-modifying antirheumatic drug; BMI, Body Mass Index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MTX, methotrexate; TCZ-IV, intravenous tocilizumab; TCZ-SC, subcutaneous tocilizumab.